Welcome to our dedicated page for Amneal Pharmaceuticals news (Ticker: AMRX), a resource for investors and traders seeking the latest updates and insights on Amneal Pharmaceuticals stock.
Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) is a global biopharmaceutical company headquartered in Bridgewater, New Jersey, with news flow that reflects activity across its Affordable Medicines, Specialty, and AvKARE segments. This page aggregates company-specific coverage so readers can follow how Amneal’s development, manufacturing, and distribution efforts translate into regulatory milestones, clinical results, and financial performance.
News about Amneal frequently centers on U.S. FDA approvals and regulatory updates. Recent announcements include approvals for denosumab biosimilars referencing Prolia and XGEVA, epinephrine injection in single- and multi-dose vials for hospitals, iohexol injection as a first generic version of Omnipaque, albuterol sulfate inhalation aerosol as a generic equivalent of PROAIR HFA, and cyclosporine ophthalmic emulsion 0.05% as a generic equivalent of RESTASIS. These items illustrate the company’s focus on complex injectables, biosimilars, respiratory therapies, and ophthalmic products within its Affordable Medicines segment.
In the Specialty segment, news coverage highlights branded CNS and endocrine therapies, particularly CREXONT for Parkinson’s disease. Amneal has reported positive interim Phase 4 ELEVATE-PD results and emphasizes CREXONT’s role in improving motor symptom control and "Good On" time. The company also reports on collaborations, such as a research collaboration and option agreement with KeifeRx to advance KFRX06, a brain-penetrant LRRK2 program for Parkinson’s disease.
Investors and analysts will also find financial results and capital markets updates, including quarterly earnings releases, guidance updates, and details of term loan and senior secured notes financings. Governance and corporate events, such as participation in healthcare investor conferences and board changes, are disclosed through press releases and Form 8-K filings.
For users tracking AMRX, this news feed provides a centralized view of regulatory decisions, product launches, clinical data, financing transactions, and strategic collaborations that shape Amneal’s business across its three segments.
Amneal Pharmaceuticals (NYSE: AMRX) reported preliminary financial results for Q1 2023, expecting net revenues of
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) will release its first quarter 2023 financial results on May 5, 2023, before market open. The company will host a conference call at 8:30 a.m. ET on the same day. Interested parties can access the live webcast through the Investor Relations section of their website.
For conference call access, dial 1 (833) 470-1428 in the U.S.; international numbers are available via a provided link. The access code for the call is 957420. A replay will be available for seven days at 1 (866) 813-9403, with the access code 704782.
Amneal, based in Bridgewater, NJ, offers a wide range of generic and specialty pharmaceuticals, focusing on complex product categories and unmet medical needs.
Amneal Pharmaceuticals (NYSE: AMRX) announced that the FDA has accepted its ANDA for a 4mg naloxone hydrochloride nasal spray, a generic version of Narcan, used for opioid overdose treatment. This product addresses the opioid crisis, with annual U.S. sales reaching $318 million as of December 2022, according to IQVIA. The company plans to launch the product at a significant scale, enhancing access to this essential medication. Amneal is committed to expanding its portfolio within the pharmaceutical sector, focusing on complex generics and specialty drugs.
Amneal Pharmaceuticals (AMRX) reported Q4 2022 net revenue of $610 million, up 14% year-over-year, driven by new Generic launches and Specialty products. Despite a net loss of $4 million for Q4, adjusted net income was $71 million, highlighting operational improvements. For the full year, revenue reached $2.21 billion, a 6% increase, but the company faced a net loss of $130 million, largely due to a $263 million anti-trust settlement. For 2023, Amneal guides net revenue of $2.25 to $2.35 billion and adjusted EBITDA of $500 to $530 million.
Amneal Pharmaceuticals (NYSE: AMRX) will announce its fourth quarter and full year 2022 financial results on March 2, 2023, before the market opens. A conference call and live webcast will take place at 8:30 a.m. Eastern Time on the same day. Investors can access the call via the Investor Relations section of the company's website here. To join the call, U.S. callers can dial 1 (844) 200-6205 and international callers 1 (929) 526-1599, using the access code 477511. A replay will be available for seven days following the call.
Amneal Pharmaceuticals (NYSE: AMRX) has entered a long-term licensing agreement with Orion Corporation to commercialize complex generic products in Europe, Australia, and New Zealand. This collaboration marks a significant step in Amneal's strategic priority for international expansion. The initial portfolio will consist of existing generic products available in the U.S. and selected pipeline products, with registrations starting in 2023. Financial terms of the deal were not disclosed, but both companies express optimism about the partnership's potential in the second-largest pharmaceutical market.
Amneal Pharmaceuticals (NYSE: AMRX) reported a successful year in 2022, launching 26 new generic products, with 8 in Q4 alone, including clindamycin phosphate gel and ipratropium bromide nasal sprays. The company received FDA approval for its first large volume bag product, esmolol hydrochloride in sodium chloride injection, expected to generate annual sales of $57 million. For 2023, Amneal anticipates over 30 new product launches, signaling ongoing innovation and growth in its injectables business.
Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced its participation in two upcoming investor conferences. The Piper Sandler 34th Annual Healthcare Conference will be held on December 1, 2022 in New York, while the 41st Annual J.P. Morgan Healthcare Conference is scheduled for January 10, 2023 in San Francisco, with a presentation at 2:15 PM PT. A live webcast of the J.P. Morgan presentation will be available on the company's website, with a replay accessible for 90 days.
Amneal is a fully integrated essential medicines company based in Bridgewater, NJ, focusing on generic and specialty pharmaceuticals.
Amneal Pharmaceuticals (NYSE: AMRX) has launched its second U.S. oncology biosimilar, RELEUKO® (filgrastim-ayow), designed to treat neutropenia in chemotherapy patients. Developed with Kashiv Biosciences, RELEUKO® aims to enhance patient access to essential cancer treatment. According to IQVIA®, annual sales for filgrastim reached $390 million in the U.S. as of August 2022, with biosimilar sales at $272 million.
The launch is a pivotal step in expanding Amneal's biosimilars business.
Amneal Pharmaceuticals has announced the FDA's acceptance of the New Drug Application for IPX203, a novel oral formulation aimed at treating Parkinson's disease. This extended-release treatment promises longer symptom control with fewer doses compared to immediate-release formulations. The FDA has set a PDUFA date of June 30, 2023 for review. The RISE-PD trial demonstrated that IPX203 provides significantly more 'Good On' time and less 'Off' time while being less frequently dosed. The trial included 506 patients across several countries, further supporting product efficacy.
FAQ
What is the current stock price of Amneal Pharmaceuticals (AMRX)?
What is the market cap of Amneal Pharmaceuticals (AMRX)?
